ProQR Therapeutics (PRQR) Interest Expenses (2014 - 2026)

ProQR Therapeutics (PRQR) has reported Interest Expenses for 12 consecutive years, with $53483.9 the latest figure, recorded in Q1 2026.

• Quarterly Interest Expenses fell 77.62% year-over-year to $53483.9 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 million (down 11.26% YoY) and the FY2025 annual result came in at $1.5 million, up 18.73% from the prior year.
• Interest Expenses eased to $53483.9 in Q1 2026 per PRQR's latest filing, from $1.9 million in the prior quarter.
• Over the last five years, Interest Expenses for PRQR reached as high as $9.9 million in Q4 2022 and fell as low as -$1.4 million in Q2 2022.
• A 4-year average of $952205.1 and a median of $59173.6 in 2025 frame the typical range for Interest Expenses.
• The largest YoY upside for Interest Expenses was 1721.5% in 2022 against a maximum downside of 115.13% in 2022.
• Year by year, Interest Expenses stood at $9.9 million in 2022, then plunged by 80.69% to $1.9 million in 2024, then grew by 1.43% to $1.9 million in 2025, then slumped by 97.23% to $53483.9 in 2026.
• According to Business Quant data, Interest Expenses over the past three periods registered $53483.9, $1.9 million, and -$171831.1 for Q1 2026, Q4 2025, and Q3 2025 respectively.